Novel receptor activity mapping of methysergide and its metabolite, methylergometrine, provides a mechanistic rationale for both the clinically observed efficacy and risk of fibrosis in patients with migraine
Guzman, M., Armer, T.A., Borland, S.W., Fishman, R.S., Leyden, M.J.
Xoc Pharmaceuticals, Inc.,
Poster presentation at American Headache Society 61st Annual Scientific Meeting, Philadelphia, PA, July 11-14th 2019
Development of a novel clinical-stage drug for the prevention of migraine based on receptor activity mapping and achievement of a target receptor profile
Armer, T.A., Guzman, M., Borland, S.W., Fishman, R.S., Leyden, M.J.
Xoc Pharmaceuticals, Inc.
Poster presentation at American Headache Society 61st Annual Scientific Meeting, Philadelphia, PA, July 11-14th 2019
Serotonin receptor activity profiles (5-HT2B and 5-HT2A) for nine commercialized ergot alkaloids correspond to known risks of fibrosis and hallucinations
Armer, T.A., Guzman, M., Borland, S.W., Fishman, R.S., Leyden, M.J., Rapoport, A.M.*
Xoc Pharmaceuticals, Inc., *The David Geffen School of Medicine at UCLA
Poster presentation at American Headache Society 61st Annual Scientific Meeting, Philadelphia, PA, July 11-14th 2019